Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

pantoprazole

This page shows the latest pantoprazole news and features for those working in and with pharma, biotech and healthcare.

Novartis reveals plans for a zero-profit COVID-19 drugs portfolio

Novartis reveals plans for a zero-profit COVID-19 drugs portfolio

The generic medicines to be included in the portfolio are Amoxicillin, Ceftriaxone, Clarithromycin, Colchicine, Dexamethasone, Dobutamine, Fluconazole, Heparin, Levofloxacin, Loperamide, Pantoprazole, Prednisone, Prednisolone, Salbutamol and

Latest news

  • Pfizer settles US Protonix lawsuit for $785m Pfizer settles US Protonix lawsuit for $785m

    over-charged Medicaid for Protonix (pantoprazole), failing to offer the federal government the same discounts it was offering to private customers.

  • Pfizer 2014 guidance threatened by Celebrex competition Pfizer 2014 guidance threatened by Celebrex competition

    The early onset of generic competition to Celebrex comes after a torrid time for Pfizer in terms of patent losses, with cholesterol lowerer Lipitor (atorvastatin), gastrointestinal medicine Protonix (pantoprazole), Viagra (sildenafil)

  • Teva defends Copaxone from Dutch patent challenge Teva defends Copaxone from Dutch patent challenge

    Maintaining Copaxone revenues is particularly important for Teva after it was ordered to pay $1.6bn in compensation to Pfizer and Takeda for infirming the patent on their Protonix (pantoprazole) gastrointestinal

  • Takeda expands Latin American footprint

    These will be ulcer treatments Zurcal (pantoprazole) and Riopan (Magaldrate Dimeticone), the anti-inflammatory Faktu (Policresulen, Cinchocaine hydrochloride) and Albothyl (Policresulen), a gynaecology product.

  • Pfizer sales dip as net income surges in Q2 Pfizer sales dip as net income surges in Q2

    from the spin-out of Zoetis and a litigation settlement with Teva and Sun Pharmaceutical Industries for patent infringement of Protonix (pantoprazole) fell 5 per cent.

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2013 Pharma deals during June 2013

    Top of the table is the patent settlement between Pfizer/ Takeda and Teva/ Sun Pharmaceutical for the launch of generic versions of Protonix (the proton pump inhibitor, pantoprazole) in 2007 ahead

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    For Nycomed this meant loss of exclusivity (LOE) on its blockbuster gastroinestinal drug pantoprazole and the consequent need to reorganise its business.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Quick links

Infographics

Multimedia